Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RY_SW01 cell injection for active lupus nephritis (Phase I/II, China)
CTR20223081Phase 2Active
- Sponsor
- Ruiyuan Biotech
- Start
- Dec 2022
- Modality
- Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of 89zr-oxine-ry_sw01 in lupus nephritis (LN), sponsored by Ruiyuan Biotech. Started Dec 2022; status: active.
02
Drugs
89zr-oxine-ry_sw01
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on CTR20223081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223081.